Recent findings suggest that in GBM patients, DKK3 is more likely to be correlated with the expression of various WNT/β-catenin pathway-related genes and is associated with immunological downregulation, while DKK3 expression can significantly impact immunosuppression and predict a dismal prognosis [287,288]. The gene discussed is DKK3; the disease is glioblastoma.